📰 Adicet Bio News
Page 3 - Adicet Bio News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Adicet Bio. Real-time updates on events, politics, business and more.
February 15, 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced the appointm...
February 14, 2024
Adicet Bio, Inc. (NASDAQ:ACET – Get Free Report) has earned an average rating of “Moderate Buy” from the seven ratings firms that are presently covering the company, MarketBeat reports. Three analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price objective among […]
February 6, 2024
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a...
February 2, 2024
Adicet Bio (NASDAQ:ACET – Get Free Report) had its price objective lowered by research analysts at HC Wainwright from $26.00 to $10.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective points to a potential upside of 228.95% from […]
February 2, 2024
Adicet Bio (NASDAQ:ACET – Get Free Report) had its price objective reduced by analysts at HC Wainwright from $26.00 to $10.00 in a note issued to investors on Friday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective indicates a potential upside of 228.95% from the stock’s current […]
January 31, 2024
Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an...
January 27, 2024
Adicet Bio, Inc. (NASDAQ:ACET – Get Free Report) Director Orbimed Advisors Llc bought 3,125,000 shares of the company’s stock in a transaction on Thursday, January 25th. The stock was purchased at an average cost of $2.40 per share, with a total value of $7,500,000.00. Following the completion of the transaction, the director now owns 7,526,359 […]
January 27, 2024
Adicet Bio, Inc. (NASDAQ:ACET – Get Free Report) Director Orbimed Advisors Llc purchased 3,125,000 shares of the business’s stock in a transaction that occurred on Thursday, January 25th. The shares were bought at an average price of $2.40 per share, for a total transaction of $7,500,000.00. Following the completion of the purchase, the director now […]
January 27, 2024
Adicet Bio, Inc. (NASDAQ:ACET – Get Free Report) Director Orbimed Advisors Llc purchased 3,125,000 shares of the business’s stock in a transaction that occurred on Thursday, January 25th. The shares were bought at an average price of $2.40 per share, for a total transaction of $7,500,000.00. Following the completion of the purchase, the director now […]
January 25, 2024
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Jan 25, 2024--